Landos Biopharma Inc

Landos Biopharma is a late clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Leveraging our AI-based integrated computational platform, LANCE, we have identified seven novel clinical and preclinical candidates across various areas of unmet medical need.

Landos has applied its LANCE platform, focused on immunity and metabolism, to identify important new molecular targets. Through advanced computational modeling-based predictions of immune cell differentiation, tissue-level cellular interactions and molecular signaling cascades, Landos has projected the ability of key targets, LANCL2, NLRX1 and PLXDC2, to address multiple disorders linked to immune function.

The LANCL2 (Lanthionine Synthetase C-Like 2) pathway is a surface membrane-associated receptor that is responsible for modulating key cellular and molecular genes tied to autoimmune disease. Specifically, LANCL2 activation leads to a decrease of inflammation-promoting TNF-alpha, INF-gamma, IL-6 and MCP1 and an increase in regulatory T regulatory cell anti-inflammatory activities. With robust control of both immune and metabolic signaling, Landos believes the novel LANCL2 pathway is relevant in a wide range of autoimmune, inflammatory and metabolic diseases. The Company has prioritized inflammatory bowel disease as its first indication in the LANCL2 pathway due to the significant unmet clinical need and major therapeutic gaps in both UC and CD.

Landos LANCL2 Lanthionine Synthetase C-Like 2 pathway